Quetiapine in Patients with Borderline Personality Disorder: An Open-Label Trial

References

• Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997;42(4):233–246.
   Google Scholar
• Bowden CL, Grunze H, Mullen J, Brecher M, Paulsson B, Jones M, Vagero M, Svensson K. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005;66(1):111–121.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Keck PE, Jr., Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162(7): 1351–1360.
   Google Scholar
• Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Que-tiapine in patients with schizophrenia. A high- and low-dose dou-ble-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997;54(6):549–557.
   Google Scholar
• Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized con-trolled trials. Schizophr Res 1999;35(1):51–68.
   Google Scholar
• Meats P Quetiapine ("Seroquel"): An effective and well-tolerated atyp-ical antipsychotic. Int J Psychiatry Clin Practice 1997;1: 231–239.
   Google Scholar
• Schulz SC, Thomson R, Brecher M The efficacy of quetiapine vs haloperidol and placebo: a meta-analytic study of efficacy. Schizophr Res 2003;62(1-2):1–12.
   Google Scholar
• Brecher M, Rak, I., Melvin, K., Jones A.M. The long-term effect of quetiapine ("Seroquel") monotherapy patients with schizophre-nia. Int J Psychiatry Clin Practice 2000;4: 287–291.
   PubMed Web of Science ®Google Scholar
• Torgerson G, Kringelen, E., Cramer, V. The prevalence of per-sonality disorders in a community sample. Arch Gen Psychiatry 2001;58:590–596.
   Google Scholar
• American_Psychiatric_Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. American Psychiat-ric Association; 1994.
   Google Scholar
• Linehan MM, Armstrong HE, Suarez A, Allmon D, Heard HL. Cognitive-behavioral treatment of chronically parasuicidal bor-derline patients. Arch Gen Psychiatry 1991;48(12):1060–1064.
   Google Scholar
• Blum N, Pfohl B, John DS, Monahan P, Black DW. STEPPS: A cognitive-behavioral systems-based group treatment for outpa-tients with borderline personality disorder--a preliminary report. Compr Psychiatry 2002;43(4):301–310.
   Google Scholar
• Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry 1997;54(12):1081–1088.
   PubMed Web of Science ®Google Scholar
• Markovitz PJ, Calabrese JR, Schulz SC, Meltzer HY. Fluoxetine in the treatment of borderline and schizotypal personality disor-ders. Am J Psychiatry 1991;148(8):1064–1067.
   Google Scholar
• Rinne T, van den Brink W, Wouters L, van Dyck R. SSRI treat-ment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline per-sonality disorder. Am J Psychiatry 2002;159(12):2048–2054.
   PubMed Web of Science ®Google Scholar
• Salzman C, Wolfson AN, Schatzberg A, Looper J, Henke R, Albanese M, Schwartz J, Miyawaki E. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 1995;15(1):23–29.
   PubMed Web of Science ®Google Scholar
• Markovitz PJ, Wagner SC. Venlafaxine in the treatment of borderline personality disorder. Psychopharmacol Bull 1995; 31(4):773–777.
   PubMedGoogle Scholar
• Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disor-der: a double-blind placebo-controlled pilot study. J Clin Psychia-try 2002;63(5):442–446.
   PubMed Web of Science ®Google Scholar
• Pinto OC, Akiskal HS. Lamotrigine as a promising approach to bor-derline personality: an open case series without concurrent DSM-IV major mood disorder. J Affect Disord 1998;51(3): 333–343.
   PubMed Web of Science ®Google Scholar
• Zanarini MC. Update on pharmacotherapy of borderline personal-ity disorder. Curr Psychiatry Rep 2004;6(1):66–70.
   PubMedGoogle Scholar
• Goldberg SC, Schulz SC, Schulz PM, Resnick RJ, Hamer RM, Friedel RO. Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch Gen Psychia-try 1986;43(7):680–686.
   PubMed Web of Science ®Google Scholar
• Soloff PH, George A, Nathan RS, Schulz PM, Ulrich RF, Perel JM. Progress in pharmacotherapy of borderline disorders. A dou-ble-blind study of amitriptyline, haloperidol, and placebo. Arch Gen Psychiatry 1986;43(7):691–697.
   PubMed Web of Science ®Google Scholar
• Rocca P. Marchiaro L, Cocuzza E, Bogetto F. Treatment of bor-derline personality disorder with risperidone. J Clin Psychiatry 2002;63(3):241–244.
   Google Scholar
• Bogenschutz MP, George Nurnberg H. Olanzapine versus pla-cebo in the treatment of borderline personality disorder. J Clin Psychiatry 2004;65(1):104–109.
   PubMed Web of Science ®Google Scholar
• Schulz SC, Camlin KL, Berry SA, Jesberger JA. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry 1999;46(10):1429–1435.
   PubMed Web of Science ®Google Scholar
• Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: A double-blind, placebo-controlled pilot study. J Clin Psychiatry 2001;62(11):849–854.
   PubMed Web of Science ®Google Scholar
• Nickel MK, Muehlbacher M, Nickel C, Kettler C, Pedrosa Gil F, Bachler E, Buschmann W, Rother N, Fartacek R, Egger C, Anvar J, Rother WK, Loew TH, Kaplan P. Aripiprazole in the treat-ment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2006;163(5): 833–838.
   PubMed Web of Science ®Google Scholar
• Villeneuve E, Lemelin S. Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impul-sivity as main target. J Clin Psychiatry 2005;66(10):1298–1303.
   PubMed Web of Science ®Google Scholar
• Hilger E, Bamas C, Kasper S. Quetiapine in the treatment of bor-derline personality disorder. World J Biol Psychiatry 2003;4(1): 42–44.
   PubMed Web of Science ®Google Scholar
• Gruettert T, Friege, L. Quetiapine in patients with borderline per-sonality disorder and psychosis: a case series. International Journal of Psychiatry in Clinical Practice 2005;9(3):180–186.
   Google Scholar
• Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of que-tiapine in the treatment of borderline personality disorder: A pilot study. J Clin Psychiatry 2006;67(7):1042–1046.
   Google Scholar
• Mauri MC, Volonteri LS, Fiorentini A, Pirola R, Bareggi SR. Two weeks' quetiapine treatment for schizophrenia, drug-induced psychosis and borderline personality disorder: a naturalistic study with drug plasma levels. Expert Opin Pharmacother 2007; 8(14):2207–2213.
   Google Scholar
• Perrella C, Carrus D, Costa E, Schifano F. Quetiapine for the treat-ment of borderline personality disorder; an open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(1):158–163.
   PubMed Web of Science ®Google Scholar
• Overall JE, Gorham, DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:199–812.
   Google Scholar
• APA. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-II/). Washington, DC: American Psychiatric Asso-ciation; 1994.
   Google Scholar
• Barratt ES. Anxiety and impulsiveness related to psychomotor efficiency. Percept Mot Skills 1959; 9:191–198.
   Google Scholar
• Baron M, Asnis, L., Gruen, R. Schedule of interviewing schizo-typal personalities: A diagnostic interview for schizotypal fea-tures. Psychiatry Res 1981;4:213–228.
   Google Scholar
• Schulz SC, Camlin, KL, Berry, SA Friedman, L. A double-blind study of risperidone for BPD (N1R270). In: 151st Annual Meeting of the American Psychiatric Association, 1998; Toronto, Ontario, Canada.
   Google Scholar